Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

Appointment adds three decades of financial and operational leadership to Soleno’s Board

REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.   

“I am very pleased to welcome Mark to the Soleno Board as we continue to execute a strong commercial launch of VYKAT XR,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “With his broad and diverse financial leadership experience, including as CFO of commercial-stage companies developing therapeutics for rare and serious diseases, I believe Mark’s background perfectly aligns with our current needs, and I look forward to his contributions.”               

“Having seen first-hand the positive impact that innovation can have on the lives of people living with rare diseases, I could not be more excited to join the Soleno Board at this stage in the Company’s evolution as a commercial organization,” added Mr. Hahn. “I look forward to working with Anish, my fellow Board members, and the Soleno leadership team to maximize the reach of VYKAT XR and offer new hope to the PWS community, including patients, their physicians and caregivers.”

Prior to joining the Soleno Board, Mr. Hahn served as Chief Financial Officer of Verona Pharma PLC, through the phase 3 program and launch of its first approved product, from March 2020 until its acquisition by Merck & Co., Inc. for approximately $10 billion in October 2025. From January 2018 until its acquisition by Swedish Orphan Biovitrum (Sobi) for up to $915 million in November 2019, Mr. Hahn served as CFO of Dova Pharmaceuticals, where he was instrumental in raising capital and in the launch of Dova’s first commercial rare disease product. From 2010 until its acquisition by Melinta Therapeutics in 2017, Mr. Hahn was CFO of Cempra, Inc. where he led the company’s IPO and several subsequent follow-on offerings. Prior to Cempra, Mr. Hahn was the CFO of several other public and private companies. Mr. Hahn began his career at Ernst & Young.